Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.

Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators.

N Engl J Med. 2016 Feb 11;374(6):511-22. doi: 10.1056/NEJMoa1505533.

2.

The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.

Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L, Hemeryck A, Jacobs S, Baumeister J, Ulrichts H.

Arthritis Res Ther. 2015 May 20;17:135. doi: 10.1186/s13075-015-0651-0.

3.

Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs.

Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P.

Blood. 2013 Jun 20;121(25):5088-97. doi: 10.1182/blood-2012-11-464545. Epub 2013 Apr 15.

4.

Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura.

Callewaert F, Roodt J, Ulrichts H, Stohr T, van Rensburg WJ, Lamprecht S, Rossenu S, Priem S, Willems W, Holz JB.

Blood. 2012 Oct 25;120(17):3603-10. doi: 10.1182/blood-2012-04-420943. Epub 2012 Sep 4.

5.

The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention.

van Loon JE, de Jaegere PP, Ulrichts H, van Vliet HH, de Maat MP, de Groot PG, Simoons ML, Leebeek FW.

Thromb Haemost. 2011 Jul;106(1):165-71. doi: 10.1160/TH10-12-0804. Epub 2011 Jun 9.

PMID:
21655675
6.

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs.

Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, Verschueren K, Stanssens P, Baumeister J, Holz JB.

Blood. 2011 Jul 21;118(3):757-65. doi: 10.1182/blood-2010-11-317859. Epub 2011 May 16.

7.

CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.

Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ.

Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20565-70. doi: 10.1073/pnas.1012865107. Epub 2010 Nov 8.

8.

Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention.

Muller O, Hamilos M, Bartunek J, Ulrichts H, Mangiacapra F, Holz JB, Ntalianis A, Trana C, Dierickx K, Vercruysse K, De Bruyne B, Wijns W, Barbato E.

Am J Cardiol. 2010 Feb 1;105(3):333-8. doi: 10.1016/j.amjcard.2009.09.033. Epub 2009 Dec 22.

PMID:
20102944
9.

Inhibition of platelet glycoprotein Ib and its antithrombotic potential.

Vanhoorelbeke K, Ulrichts H, Van de Walle G, Fontayne A, Deckmyn H.

Curr Pharm Des. 2007;13(26):2684-97. Review.

PMID:
17897012
10.

Role of glycoprotein Ibalpha in phagocytosis of platelets by macrophages.

Badlou BA, Spierenburg G, Ulrichts H, Deckmyn H, Smid WM, Akkerman JW.

Transfusion. 2006 Dec;46(12):2090-9.

PMID:
17176320
11.

Platelet microparticle formation and thrombin generation under high shear are effectively suppressed by a monoclonal antibody against GPIba.

Pontiggia L, Steiner B, Ulrichts H, Deckmyn H, Forestier M, Beer JH.

Thromb Haemost. 2006 Dec;96(6):774-80.

PMID:
17139372
12.

Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential anti-thrombotic drugs.

De Meyer SF, Vanhoorelbeke K, Ulrichts H, Staelens S, Feys HB, Salles I, Fontayne A, Deckmyn H.

Cardiovasc Hematol Disord Drug Targets. 2006 Sep;6(3):191-207. Review.

PMID:
17017902
13.

Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V.

Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, Vanhoorelbeke K, Deckmyn H.

J Biol Chem. 2006 Feb 24;281(8):4699-707. Epub 2005 Dec 22.

14.

Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1.

Keuren JF, Wielders SJ, Ulrichts H, Hackeng T, Heemskerk JW, Deckmyn H, Bevers EM, Lindhout T.

Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1499-505. Epub 2005 Apr 21.

PMID:
15845904
15.

How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects?

Xu G, Ulrichts H, Vauterin S, De Meyer SF, Deckmyn H, Teng M, Niu L.

Toxicon. 2005 Apr;45(5):561-70.

PMID:
15777951
16.

The von Willebrand factor self-association is modulated by a multiple domain interaction.

Ulrichts H, Vanhoorelbeke K, Girma JP, Lenting PJ, Vauterin S, Deckmyn H.

J Thromb Haemost. 2005 Mar;3(3):552-61.

17.

Identification of residues within human glycoprotein VI involved in the binding to collagen: evidence for the existence of distinct binding sites.

Lecut C, Arocas V, Ulrichts H, Elbaz A, Villeval JL, Lacapère JJ, Deckmyn H, Jandrot-Perrus M.

J Biol Chem. 2004 Dec 10;279(50):52293-9. Epub 2004 Oct 4.

18.

New approaches for antithrombotic antiplatelet therapies.

Ulrichts H, Vanhoorelbeke K, Van De Walle G, Katsutani S, De Meyer S, Staelens S, Deckmyn H.

Curr Med Chem. 2004 Sep;11(17):2261-3. Review.

PMID:
15379711
19.

A monoclonal antibody directed against human von Willebrand factor induces type 2B-like alterations.

Ulrichts H, Harsfalvi J, Bene L, Matko J, Vermylen J, Ajzenberg N, Baruch D, Deckmyn H, Tornai I.

J Thromb Haemost. 2004 Sep;2(9):1622-8.

20.

Platelet antigens and their function.

Deckmyn H, Ulrichts H, Van De Walle G, Vanhoorelbeke K.

Vox Sang. 2004 Jul;87 Suppl 2:105-11. Review. No abstract available.

PMID:
15209892
21.

The GPIbalpha-thrombin interaction: far from crystal clear.

Vanhoorelbeke K, Ulrichts H, Romijn RA, Huizinga EG, Deckmyn H.

Trends Mol Med. 2004 Jan;10(1):33-9. Review. No abstract available.

PMID:
14720584
22.

von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism.

Ulrichts H, Vanhoorelbeke K, Cauwenberghs S, Vauterin S, Kroll H, Santoso S, Deckmyn H.

Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1302-7. Epub 2003 May 29.

PMID:
12775575
23.

Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs.

Vanhoorelbeke K, Ulrichts H, Schoolmeester A, Deckmyn H.

Curr Drug Targets Cardiovasc Haematol Disord. 2003 Jun;3(2):125-40. Review.

PMID:
12769639
24.

Integrin alphaIIbbeta3 and shear-dependent action of glycoprotein Ibalpha stimulate platelet-dependent thrombin formation in stirred plasma.

Keuren JF, Ulrichts H, Feijge MA, Hamulyak K, Deckmyn H, Lindhout T, Heemskerk JW.

J Lab Clin Med. 2003 May;141(5):350-8.

PMID:
12761479
25.

Selection of phages that inhibit vWF interaction with collagen under both static and flow conditions.

Ulrichts H, Depraetere H, Harsfalvi J, Deckmyn H.

Thromb Haemost. 2001 Aug;86(2):630-5.

PMID:
11522014
26.

Combination chemotherapy with vindesine-ifosfamide-cisplatin (VIP) in locally advanced unresectable stage III and in stage IV non-small cell lung cancer: a phase II trial.

Vansteenkiste J, Vandebroek J, Mariën S, Roex L, Bertrand P, Bockaert J, De Beukelaar T, Deman R, De Muynck P, Ulrichts H, et al.

Lung Cancer. 1995 Dec;13(3):295-303.

PMID:
8719069

Supplemental Content

Loading ...
Support Center